Top Ten most popular articles on this week

pharmafile | September 21, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jobs, Novartis, Novo Nordisk, Senate, UCB, manufacturing, opioid crisis, top 10 

Manufacturing took a hit this week as Novo Nordisk announced the loss of 400 jobs while Novartis made the move from Arnhem to Amsterdam affecting another 400 jobs in the Netherlands. On top of all that Hurricane Florence shut down manufacturing plants in the American South as storms battered to Carolina coast forcing production to halt and wait out the storm.

Nevertheless, shares in the Israeli pharma firm Teva soared after the approval of its migraine treatment Ajovy while the US senate passed a bipartisan bill aimed at tackling the opioid Crisis. To find out more, check out this week’s Top 10 most popular articles on now!

10. 400 jobs to go as Novo Nordisk overhauls R&D operations

Novo Nordisk has revealed its intention to restructure its research & development operations “to accelerate the expansion and diversification of its pipeline across serious chronic diseases”. This move, of course, does not come without restructuring, and will result in the loss of 400 employees.

9. UCB brings promising plaque psoriasis data to EADV 2018

UCB has revealed new findings for its products Cimzia and bimekizumab in the treatment of moderate-to-severe chronic plaque psoriasis.

8. Novartis to relocate Arnhem operations to Amsterdam, 400 jobs affected

Novartis has announced it is to relocate its operations in Arnhem in the Netherlands to the capital city of Amsterdam, according to Dutch regional public broadcaster Omroep Gelderland, uprooting the site from the base it has occupied since the 1950s.

7. Sanofi’s Dupixent improves symptoms for adolescent atopic dermatitis patients

Sanofi’s Dupixent (dupilumab) has made a strong showing as a monotherapy at Phase 3 in the treatment of moderate-to-severe atopic dermatitis in patients aged 12-17 whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable – an indication where there are currently no approved systemic biologic treatments.

6. Pfizer, Novartis, MSD, Novo and GSK halt operations in wake of Hurricane Florence

As Hurricane Florence begins to breach the Southeast Coast, major pharma firms have announced they are enacting contingency plans, including  shutting down operations at their manufacturing sites across North Carolina and the relocation of drug products in affected areas.

5. NICE rejects CAR-T therapy Kymriah for DLBCL in adults

The National Institute for health and Care Excellence (NICE) has rejected Novartis’ CAR-T therapy Kymriah for use in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

4. Novartis doubles down on Cosentyx’s efficacy in psoriasis with extensive real-world data

Novartis has revealed data from a range of multinational, real-world studies which reinforced the efficacy of its interleukin-17A inhibitor Cosentyx (secukinumab) in the treatment of moderate-to-severe psoriasis.

3. Ex-GSK R&D head joins OxStem as CSO

OxStem, a regenerative drug discovery unit spun out from the University of Oxford, has brought on board ex-GlaxoSmithKline R&D exec Georg Terstappen as its new Chief Scientific Officer

2. Teva shares soar after migraine treatment Ajovy approval

Shares in the Israeli pharma firm Teva soared on Sunday after the announcement that the US Food and Drug Administration (FDA) had approved the company’s migraine treatment Ajovy.

1. US Senate pass bipartisan bill to tackle opioid crisis

The US Senate have passed a bipartisan bill aimed at combatting the opioid crisis through new research, treatment and help for families suffering from the effects of the opioid addiction epidemic that has swept through United States in recent years.

Related Content

Touchlight completes expansion of one of world’s largest DNA manufacturing facilities in London

Touchlight, a company that focuses on pioneering enzymatic DNA production, has announced that it has …

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human …


AstraZeneca, Klarify, and Novartis Gene Therapies top Digital Awards leaderboard

Pharmaceutical companies AstraZeneca, Klarify, and Novartis Gene Therapies all received two gold awards at the …

Latest content